• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effect of antithrombotic and antiplatelet agents for ischemic stroke in atrial fibrillation patients with dialysis
With great interest, we read Chen et al. study about antithrombotic agents in patients with end stage renal disease (ESRD) and atrial fibrillation (AF) [1]. The authors found that anti-platelet or warfarin treatment could not lower the risk of ischemic stroke in patients with ESRD. We have some concerns about this study.
Source: International Journal of Cardiology - April 28, 2015 Category: Cardiology Authors: Chin-Wei Hsu, Yaw-Bin Huang, Chung-Yu Chen Tags: Letter to the Editor Source Type: research

‘Some doors are better left closed’: Using LAA occluders as an alternative to warfarin in very high-risk dialysed patients with atrial fibrillation
Since 2011, when the EMA approved the treatment with novel oral anticoagulants (NOACs) for primary prevention of cardio-embolic stroke in patients with atrial fibrillation (AF), a reasonable question repeatedly arose: “Will NOACs become the new standard of care in anticoagulation therapy?” [1]. While for many cathegories of patients the answer soon become positive [2], the sub-group of advanced chronic kidney disease (CKD) 5D stage (in dialysis) has never received a “yes” from either FDA or EMA (none of t hem allowing the use of NOACs in 5D CKD).
Source: International Journal of Cardiology - April 27, 2018 Category: Cardiology Authors: Alexandru Burlacu, Adrian Covic Tags: Editorial Source Type: research